This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sutherland, R. L. Articles by Taylor, I. W. Search for Related Content PubMed PubMed Citation Articles by Sutherland, R. L. Articles by Taylor, I. W.

Cell Proliferation Kinetics of MCF-7 Human Mammary Carcinoma Cells in Culture and Effects of Tamoxifen on Exponentially Growing and Plateau-Phase Cells¹

Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, New South Wales 2006, Australia

MCF-7 human mammary carcinoma cells were inoculated into 150-sq cm flasks at 3 x 10⁵ cells/flask, and after a lag period of about 48 hr, these cells grew exponentially for 5 days with a mean population doubling time of about 24 hr. During exponential growth, 80 to 90% of cells were in the "rapidly cycling" pool, the clonogenic fraction was 50 to 60%, and the mean percentage of cells in the G₀–G₁, S, and G₂ + M phases of the cell cycle was 48.9 ± 0.6% (S.E.), 39.4 ± 0.6%, and 11.6 ± 0.3%, respectively. These parameters changed rapidly between Days 7 and 13 when plateau phase was reached. Between Days 13 and 18, 74.8 ± 0.7% of cells were in G₀–G₁, 15.3 ± 0.4% were in S, and 9.8 ± 0.6% were in G₂ + M phase. Only about 30% of these cells were cycling rapidly, and the clonogenic fraction had fallen to less than 10%.

Tamoxifen induced a dose-dependent decrease in the growth rate of exponentially growing cells, which was accompanied by a dose-dependent increase in percentage of G₀–G₁-phase cells, and a decline in percentage of S-phase cells. At doses 10 µM, a 24-hr pulse of tamoxifen was cytotoxic to exponentially growing cells. Plateau-phase cells were less sensitive to these effects of tamoxifen.

In an attempt to define the kinetic basis of the G₀–G₁ accumulation induced by tamoxifen, asynchronous MCF-7 cells were pretreated for 42 hr with various doses of tamoxifen, and the rate of efflux of cells from the G₀–G₁ phase of the cell cycle was assessed by blocking their reentry into G₁ with ICRF 159. Following treatment of control cultures with ICRF 159, two populations of cells were distinguished by their rates of efflux from G₀–G₁ phase. The majority of cells left G₀–G₁ rapidly with a mean t of 2.3 hr ("rapidly cycling" cells). However, about 18% of cells had a much slower rate of exit with a mean t of about 30 hr ("slowly cycling" cells). Pretreatment with tamoxifen resulted in a dose-dependent decrease in the proportion of rapidly cycling cells and an increase in the proportion of cells with slow G₁ transit times. Although this appeared to be the predominant effect, tamoxifen also decreased the rate at which the slowly cycling cells traversed G₁. Simultaneous treatment with estradiol returned these parameters to control values at doses of tamoxifen 5 µM, partially reversed the effect of 7.5 µM tamoxifen, but was without effect on the arrest of cell cycle progression induced by 10 µM tamoxifen. It is concluded that cells accumulate in G₀–G₁ following tamoxifen treatment due to an increase in the proportion of slowly cycling cells at the expense of a population of rapidly cycling cells, which appear to be relatively uninfluenced by the drug.

¹ Presented in part at a UCLA Symposium, "Rational Basis for Chemotherapy," Keystone, Colo., 1982 (36).

² To whom requests for reprints should be addressed.

Received 12/28/82. Accepted 5/20/83.

This article has been cited by other articles:

				A. Naresh, A. D. Thor, S. M. Edgerton, K. C. Torkko, R. Kumar, and F. E. Jones The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis Cancer Res., August 1, 2008; 68(15): 6387 - 6395. [Abstract] [Full Text] [PDF]

				Y. M. Shah, M. Al-Dhaheri, Y. Dong, C. Ip, F. E. Jones, and B. G. Rowan Selenium disrupts estrogen receptor {alpha} signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells Mol. Cancer Ther., August 1, 2005; 4(8): 1239 - 1249. [Abstract] [Full Text] [PDF]

				A. Fritah, C. Saucier, J. Mester, G. Redeuilh, and M. Sabbah p21WAF1/CIP1 Selectively Controls the Transcriptional Activity of Estrogen Receptor {alpha} Mol. Cell. Biol., March 15, 2005; 25(6): 2419 - 2430. [Abstract] [Full Text] [PDF]

				F Gadal, A Starzec, C Bozic, C Pillot-Brochet, S Malinge, V Ozanne, J Vicenzi, L Buffat, G Perret, F Iris, et al. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells J. Mol. Endocrinol., February 1, 2005; 34(1): 61 - 75. [Abstract] [Full Text] [PDF]

				L. J. Pierce, L. F. Hutchins, S. R. Green, D. L. Lew, J. R. Gralow, R. B. Livingston, C. K. Osborne, and K. S. Albain Sequencing of Tamoxifen and Radiotherapy After Breast-Conserving Surgery in Early-Stage Breast Cancer J. Clin. Oncol., January 1, 2005; 23(1): 24 - 29. [Abstract] [Full Text] [PDF]

				W. H. Shen, Y. Yin, S. R. Broussard, R. H. McCusker, G. G. Freund, R. Dantzer, and K. W. Kelley Tumor Necrosis Factor {alpha} Inhibits Cyclin A Expression and Retinoblastoma Hyperphosphorylation Triggered by Insulin-like Growth Factor-I Induction of New E2F-1 Synthesis J. Biol. Chem., February 27, 2004; 279(9): 7438 - 7446. [Abstract] [Full Text] [PDF]

				A. Thiantanawat, B. J. Long, and A. M. Brodie Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens Cancer Res., November 15, 2003; 63(22): 8037 - 8050. [Abstract] [Full Text] [PDF]

				B. D. Boyan, V. L. Sylvia, T. Frambach, C. H. Lohmann, J. Dietl, D. D. Dean, and Z. Schwartz Estrogen-Dependent Rapid Activation of Protein Kinase C in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells and Estrogen Receptor-Negative HCC38 Cells Is Membrane-Mediated and Inhibited by Tamoxifen Endocrinology, May 1, 2003; 144(5): 1812 - 1824. [Abstract] [Full Text] [PDF]

				R. Hui, G. L. Finney, J. S. Carroll, C. S. L. Lee, E. A. Musgrove, and R. L. Sutherland Constitutive Overexpression of Cyclin D1 but not Cyclin E Confers Acute Resistance to Antiestrogens in T-47D Breast Cancer Cells Cancer Res., December 1, 2002; 62(23): 6916 - 6923. [Abstract] [Full Text] [PDF]

				A. K. C. Teo, H. K. Oh, R. B. Ali, and B. F. L. Li The Modified Human DNA Repair Enzyme O6-Methylguanine-DNA Methyltransferase Is a Negative Regulator of Estrogen Receptor-Mediated Transcription upon Alkylation DNA Damage Mol. Cell. Biol., October 15, 2001; 21(20): 7105 - 7114. [Abstract] [Full Text] [PDF]

				L. J. Havrilesky, C. P. McMahon, E. K. Lobenhofer, R. Whitaker, J. R. Marks, and A. Berchuck Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones Reproductive Sciences, April 1, 2001; 8(2): 104 - 113. [Abstract] [PDF]

				J. S. Foster, D. C. Henley, A. Bukovsky, P. Seth, and J. Wimalasena Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function Mol. Cell. Biol., February 1, 2001; 21(3): 794 - 810. [Abstract] [Full Text]

				M. Sabbah, D. Courilleau, J. Mester, and G. Redeuilh Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element PNAS, September 28, 1999; 96(20): 11217 - 11222. [Abstract] [Full Text] [PDF]

				G. Lazennec, J. L. Alcorn, and B. S. Katzenellenbogen Adenovirus-Mediated Delivery of a Dominant Negative Estrogen Receptor Gene Abrogates Estrogen-Stimulated Gene Expression and Breast Cancer Cell Proliferation Mol. Endocrinol., June 1, 1999; 13(6): 969 - 980. [Abstract] [Full Text]

				O. W. J. Prall, E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry Mol. Cell. Biol., August 1, 1998; 18(8): 4499 - 4508. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				D. H. D. Nguyen, I. M. Hussaini, and S. L. Gonias Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular Motility J. Biol. Chem., April 3, 1998; 273(14): 8502 - 8507. [Abstract] [Full Text] [PDF]

				O. W.J. Prall, B. Sarcevic, E. A. Musgrove, C. K.W. Watts, and R. L. Sutherland Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2 J. Biol. Chem., April 18, 1997; 272(16): 10882 - 10894. [Abstract] [Full Text] [PDF]

				J. S. Carroll, O. W. J. Prall, E. A. Musgrove, and R. L. Sutherland A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence J. Biol. Chem., December 1, 2000; 275(49): 38221 - 38229. [Abstract] [Full Text] [PDF]

				A. Lai, B. Sarcevic, O. W. J. Prall, and R. L. Sutherland Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1 J. Biol. Chem., July 6, 2001; 276(28): 25823 - 25833. [Abstract] [Full Text] [PDF]